These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

306 related articles for article (PubMed ID: 25212258)

  • 21. Oral Glucose-lowering Drugs and Cardiovascular Outcomes: From the Negative RECORD and ACCORD to Neutral TECOS and Promising EMPA-REG.
    Tsioufis C; Andrikou E; Thomopoulos C; Papanas N; Tousoulis D
    Curr Vasc Pharmacol; 2017; 15(5):457-468. PubMed ID: 27928947
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Mechanisms and Potential Roles of Glucose-Lowering Agents in COVID-19: A Review.
    Berlie HD; Kale-Pradhan PB; Orzechowski T; Jaber LA
    Ann Pharmacother; 2021 Nov; 55(11):1386-1396. PubMed ID: 33657863
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Cardiovascular outcome trials in type 2 diabetes and the sulphonylurea controversy: rationale for the active-comparator CAROLINA trial.
    Rosenstock J; Marx N; Kahn SE; Zinman B; Kastelein JJ; Lachin JM; Bluhmki E; Patel S; Johansen OE; Woerle HJ
    Diab Vasc Dis Res; 2013 Jul; 10(4):289-301. PubMed ID: 23449634
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effects of glucose-lowering and multifactorial interventions on cardiovascular and mortality outcomes: a meta-analysis of randomized control trials.
    Seidu S; Achana FA; Gray LJ; Davies MJ; Khunti K
    Diabet Med; 2016 Mar; 33(3):280-9. PubMed ID: 26282461
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Sulfonylureas and the Risks of Cardiovascular Events and Death: A Methodological Meta-Regression Analysis of the Observational Studies.
    Azoulay L; Suissa S
    Diabetes Care; 2017 May; 40(5):706-714. PubMed ID: 28428321
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Cardiovascular effects of noninsulin, glucose-lowering agents: need for more outcomes data.
    Joshi PH; Kalyani RR; Blumenthal RS; Donner TW
    Am J Cardiol; 2012 Nov; 110(9 Suppl):32B-42B. PubMed ID: 23062565
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Pharmacologic prevention of microvascular and macrovascular complications in diabetes mellitus: implications of the results of recent clinical trials in type 2 diabetes.
    Tandon N; Ali MK; Narayan KM
    Am J Cardiovasc Drugs; 2012 Feb; 12(1):7-22. PubMed ID: 22217193
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Current cardiovascular outcomes trials in type 2 diabetes: Perspectives and insight.
    Coch RW; Green JB
    Nutr Metab Cardiovasc Dis; 2016 Sep; 26(9):767-72. PubMed ID: 27378397
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Cardiovascular benefits of exogenous insulin.
    Chaudhuri A; Dandona P; Fonseca V
    J Clin Endocrinol Metab; 2012 Sep; 97(9):3079-91. PubMed ID: 22723317
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The elephant in the room: Why cardiologists should stop ignoring type 2 diabetes.
    O'Keefe JH; Nassif ME; Magwire ML; O'Keefe EL; Lavie CJ
    Prog Cardiovasc Dis; 2019; 62(4):364-369. PubMed ID: 31408637
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Effects of anti-diabetic therapy on cardiovascular disease].
    Avogaro A
    G Ital Cardiol (Rome); 2013 Dec; 14(12 Suppl):26-36. PubMed ID: 24362784
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Diabetes patients requiring glucose-lowering therapy and nondiabetics with a prior myocardial infarction carry the same cardiovascular risk: a population study of 3.3 million people.
    Schramm TK; Gislason GH; Køber L; Rasmussen S; Rasmussen JN; Abildstrøm SZ; Hansen ML; Folke F; Buch P; Madsen M; Vaag A; Torp-Pedersen C
    Circulation; 2008 Apr; 117(15):1945-54. PubMed ID: 18378618
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A Practical Guide to the Use of Glucose-Lowering Agents With Cardiovascular Benefit or Proven Safety.
    Fitchett D; Cheng A; Connelly K; Goldenberg R; Goodman SG; Leiter LA; Lonn E; Paty B; Poirier P; Stone J; Thompson D; Yale JF; Mancini GBJ
    Can J Cardiol; 2017 Jul; 33(7):940-942. PubMed ID: 28668144
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Cardiovascular outcome trials of glucose-lowering drugs or strategies in type 2 diabetes.
    Holman RR; Sourij H; Califf RM
    Lancet; 2014 Jun; 383(9933):2008-17. PubMed ID: 24910232
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Renal and Cardiac Implications of Sodium Glucose Cotransporter 2 (SGLT2) Inhibitors: The State of the Science.
    Cruz JE; Ahuja T; Bridgeman MB
    Ann Pharmacother; 2018 Dec; 52(12):1238-1249. PubMed ID: 29911393
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Glucose-lowering therapies in patients with type 2 diabetes and cardiovascular diseases.
    Prattichizzo F; La Sala L; Rydén L; Marx N; Ferrini M; Valensi P; Ceriello A
    Eur J Prev Cardiol; 2019 Dec; 26(2_suppl):73-80. PubMed ID: 31766918
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Cardiovascular outcome trials of glucose-lowering medications: an update.
    Home P
    Diabetologia; 2019 Mar; 62(3):357-369. PubMed ID: 30607467
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Barriers to prescribing glucose-lowering therapies with cardiometabolic benefits.
    Gao Y; Peterson E; Pagidipati N
    Am Heart J; 2020 Jun; 224():47-53. PubMed ID: 32304879
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Cardiovascular risks and benefits with oral drugs for Type 2 diabetes mellitus.
    Weidman-Evans E; Metz SM; Evans JD
    Expert Rev Clin Pharmacol; 2014 Mar; 7(2):225-33. PubMed ID: 24490745
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Glycemic management in diabetes and the associated cardiovascular risk: are we helping or hurting our patients?
    Koshizaka M; Green JB; Alexander JH
    Circ J; 2012; 76(7):1572-80. PubMed ID: 22789974
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.